Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned a consensus rating of “Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $55.14.
A number of analysts have recently issued reports on the company. Zacks Investment Research upgraded Omnicell from a “strong sell” rating to a “hold” rating in a research report on Wednesday, December 27th. BidaskClub downgraded Omnicell from a “hold” rating to a “sell” rating in a research report on Friday, December 22nd. Cantor Fitzgerald restated a “buy” rating and issued a $60.00 target price on shares of Omnicell in a research report on Wednesday, December 13th. Craig Hallum restated a “buy” rating and issued a $62.00 target price (up previously from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Finally, Oppenheimer restated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a research report on Tuesday, December 5th.
Shares of Omnicell (OMCL) traded down $0.35 on Friday, hitting $48.60. The stock had a trading volume of 161,100 shares, compared to its average volume of 213,800. The company has a market cap of $1,840.00, a P/E ratio of -441.82, a PEG ratio of 3.88 and a beta of 0.71. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Omnicell has a 12-month low of $31.85 and a 12-month high of $55.40.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.42. The firm had revenue of $186.78 million during the quarter, compared to the consensus estimate of $192.45 million. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The company’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the company posted $0.40 EPS. equities research analysts expect that Omnicell will post 0.12 EPS for the current year.
In related news, VP Jorge R. Taborga sold 6,295 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $48.69, for a total value of $306,503.55. Following the completion of the sale, the vice president now owns 50,013 shares in the company, valued at approximately $2,435,132.97. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Peter J. Kuipers sold 1,926 shares of Omnicell stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $51.69, for a total value of $99,554.94. Following the completion of the transaction, the chief financial officer now directly owns 40,544 shares in the company, valued at $2,095,719.36. The disclosure for this sale can be found here. Insiders sold a total of 27,558 shares of company stock valued at $1,330,230 in the last 90 days. 3.77% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Omnicell by 2.3% in the 2nd quarter. BlackRock Inc. now owns 4,589,119 shares of the company’s stock worth $197,790,000 after purchasing an additional 101,776 shares during the period. Vanguard Group Inc. increased its stake in Omnicell by 3.7% in the 2nd quarter. Vanguard Group Inc. now owns 1,928,201 shares of the company’s stock worth $83,105,000 after purchasing an additional 67,902 shares during the period. Conestoga Capital Advisors LLC increased its stake in Omnicell by 0.7% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,617,706 shares of the company’s stock worth $82,584,000 after purchasing an additional 11,105 shares during the period. Oak Ridge Investments LLC increased its stake in Omnicell by 0.6% in the 2nd quarter. Oak Ridge Investments LLC now owns 1,537,940 shares of the company’s stock worth $66,285,000 after purchasing an additional 8,491 shares during the period. Finally, Janus Henderson Group PLC increased its stake in Omnicell by 129.6% in the 2nd quarter. Janus Henderson Group PLC now owns 1,231,933 shares of the company’s stock worth $53,096,000 after purchasing an additional 695,334 shares during the period. 99.61% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Omnicell, Inc. (OMCL) Given Average Recommendation of “Buy” by Analysts” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/12/omnicell-inc-omcl-given-average-recommendation-of-buy-by-analysts.html.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.